Skip to content

Ventricular remodeling

TL;DR — Hypertensive ventricular remodeling is heterogeneous: normal geometry, concentric remodeling, concentric LVH and eccentric LVH all occur, and the classic linear progression from concentric LVH to dilation and systolic failure is not the dominant proven path (Nadruz 2015, PMID 24804791). Pressure load interacts with obesity, kidney disease, aldosterone, sex, ancestry, salt exposure and neurohormonal signaling. The high-risk substrate is not mass alone: diffuse interstitial fibrosis, impaired strain and coronary microvascular dysfunction connect structural change to diastolic failure, ischemia and arrhythmia (González 2024, PMID 38084597; Camici 2020, PMID 31999329). Antihypertensive therapy regresses LV mass, and regression is associated with fewer events, but mediation is not established (Pierdomenico 2010, PMID 20414193). CMR makes tissue and geometry measurable; it has not yet supplied a universal treatment target.

1. Geometry: two measurements, four phenotypes

LV geometry is conventionally classified using LV mass and relative wall thickness (RWT). Exact thresholds depend on modality, sex, indexation and laboratory reference ranges (Yildiz 2020, PMID 31759953; Stewart 2018, PMID 30408469).

LV mass RWT Phenotype Typical interpretation Important caution
Normal Normal Normal geometry No morphometric LVH Strain/fibrosis may still be abnormal
Normal Increased Concentric remodeling Thicker wall relative to cavity without increased mass Threshold-sensitive
Increased Increased Concentric LVH Increased mass with high wall-to-cavity ratio Not uniquely hypertensive
Increased Normal Eccentric LVH Increased mass with relatively dilated cavity Volume load, obesity and ischemia may contribute

Concentric hypertrophy is often presented as the canonical pressure-overload response, but reviews of longitudinal evidence find it is not necessarily the most common geometry and does not commonly progress directly to dilated systolic failure without intervening coronary disease (Nadruz 2015, PMID 24804791).

2. Wall stress and cardiomyocyte growth

Increased afterload raises systolic wall stress. Cardiomyocyte thickening and parallel sarcomere addition can reduce stress per unit area, but the response becomes maladaptive when it is accompanied by fibrosis, capillary mismatch, impaired energetics, apoptosis and altered calcium handling (Nwabuo 2020, PMID 32016791; Nemtsova 2023, PMID 37048689).

Driver Remodeling effect Evidence boundary
Sustained systolic load Cardiomyocyte hypertrophy and increased LV mass Exposure often estimated from episodic BP
Pulsatile load/aortic stiffness Greater late-systolic load and ventricular–arterial coupling stress Age and vascular disease confound
RAAS/aldosterone Hypertrophy, fibroblast activation, collagen deposition Pressure-independent contribution varies
Sympathetic activation Growth signaling, ischemia and arrhythmogenic substrate Difficult to quantify clinically
Obesity Higher mass, chamber load and inflammatory signaling BSA indexation can conceal LVH
CKD Pressure/volume load, anemia, uremic and mineral signals Mixed cardiomyopathy phenotype

The amount of LV mass may exceed that predicted by sex, body size and workload. In the MAVI cohort of 1,019 hypertensive adults, 322 had “inappropriate” mass; excess mass predicted events beyond conventional risk factors and conventional LVH status (de Simone 2002, PMID 12364349).

3. Indexation changes who is labeled

Body-surface-area indexation can normalize away part of obesity-associated mass. Reviews recommend height-based alternatives when the question is hypertrophy detection in obesity, but no indexing scheme is neutral across body composition, sex and ancestry (Woodiwiss 2015, PMID 25794954).

Index Advantage Failure mode
Raw LV mass Transparent physical quantity Strong body-size dependence
Mass/BSA Familiar and widely reported Under-detects obesity-associated LVH
Mass/height²·⁷ Less dilution by adiposity Exponent and thresholds population-dependent
Sex-specific CMR threshold High reproducibility within protocol Scanner/reference portability
Predicted “appropriate” mass Incorporates workload and size Model-dependent and less widely available

Any prevalence or regression report should state formula, index and threshold rather than simply “LVH” (Yildiz 2020, PMID 31759953; de Simone 2002, PMID 12364349).

4. Fibrosis is a distinct remodeling axis

Interstitial collagen expansion is not synonymous with cardiomyocyte hypertrophy. Fibrosis increases stiffness, disrupts electrical conduction, impairs perfusion and may persist despite changes in mass (Weber 2004, PMID 15106793; González 2024, PMID 38084597).

Fibrosis measure Biological target Strength Limitation
Histology Collagen fraction and pattern Direct tissue assessment Sampling and biopsy selection
LGE-CMR Focal replacement fibrosis Spatial pattern Poor sensitivity to diffuse interstitial change
Native T1 Composite tissue signal No contrast required Vendor, field-strength and edema effects
ECV Extracellular fraction Quantifies diffuse expansion Hematocrit, sequence and reference dependence
Interstitial volume ECV × myocardial volume Integrates fraction and organ size Derived endpoint; not a clinical outcome
Serum collagen markers Turnover-related signal Scalable Limited cardiac specificity

Reviews from 2004–2024 consistently place fibroblast activation and extracellular-matrix turnover at the center of maladaptive HHD, while also emphasizing the absence of a validated fibrosis-guided treatment pathway (Weber 2004, PMID 15106793; Cuspidi 2006, PMID 16263734; Sowers 2007, PMID 17617768; González 2024, PMID 38084597).

5. Microvascular remodeling

Hypertension changes small-vessel structure and function through rarefaction, arteriolar wall thickening, endothelial dysfunction, oxidative stress and reduced nitric-oxide bioavailability (Durante 2024, PMID 39769057).

In LVH, capillary supply may not scale with myocardial growth. Diffuse intramural arteriolar remodeling and capillary rarefaction can reduce coronary flow reserve even without obstructive epicardial disease (Camici 2020, PMID 31999329).

Consequence Proposed link
Exertional ischemia without obstructive CAD Demand–supply mismatch and impaired flow reserve
Diastolic dysfunction Ischemia, fibrosis and impaired relaxation
HFpEF Microvascular inflammation–NO–cGMP–PKG signaling pathway
HFrEF transition Infarction pathway or non-infarct remodeling pathway
Arrhythmia Fibrotic and ischemic electrical heterogeneity

The comorbidity-driven HFpEF paradigm proposes systemic inflammation, coronary microvascular endothelial inflammation, reduced NO/cGMP/PKG signaling, hypertrophy and stiffness as a connected chain; it remains a mechanistic framework rather than a diagnostic sequence in every patient (Paulus 2013, PMID 23684677).

6. Strain detects dysfunction before EF falls

Global longitudinal strain (GLS) may be impaired while EF remains preserved. Treatment meta-analysis across eight studies and 1,140 hypertensive patients found BP falling from 148.4/88.7 to 127.4/77.8 mm Hg, LV-mass index from 108.4 to 100.2 g/m², and GLS from −17.7% to −19.6%; GLS improvement related to LV-mass reduction but not SBP reduction in meta-regression (Tadic 2022, PMID 35102087).

In a 1,600-patient retrospective cohort with echocardiograms 6–18 months apart, LV mass-to-strain ratio discriminated LVH change better than mass or GLS alone and predicted cardiovascular death/HF hospitalization: adjusted HR 1.044 per 1 g/m² per % and HR 2.267 for values ≥6.52 g/m² per % (Hwang 2025, PMID 40970541).

These are prognostic associations and derived thresholds; neither establishes that treating to a strain or ratio target improves events.

7. Regression evidence

Evidence Population/design Remodeling result Clinical boundary
1996 meta-analysis 39 double-blind RCTs Adjusted LV-mass reductions: ACE inhibitor 13%, CCB 9%, diuretic 7%, beta-blocker 6% Older, small, heterogeneous trials (Schmieder 1996, PMID 8622227)
2009 meta-analysis 84 comparisons; 6,001 patients Beta-blocker 9.8% vs ARB 12.5%; beta-blocker −3.6% predictor versus other classes Class comparison partly BP/duration dependent (Fagard 2009, PMID 19770405)
LIFE echo 916 with serial echo LV-mass index −21.7 vs −17.7 g/m², losartan vs atenolol; P=0.021 Substudy imaging endpoint (Devereux 2004, PMID 15326072)
Regression prognosis meta-analysis 5 studies; 3,149 patients Regression/persistent normal mass vs persistent/new LVH HR 0.54 (95% CI 0.35–0.84) Observational association; heterogeneity (Pierdomenico 2010, PMID 20414193)
Sacubitril/valsartan vs olmesartan 114 randomized LV-mass index difference favored ARNI at 12 and 52 weeks Remodeling, not event trial (Schmieder 2017, PMID 29029087)
REVERSE-LVH 78 randomized; open label Interstitial volume −5.2±5.4 vs −2.5±3.1 mL; P=0.006 at similar ambulatory SBP Phase 2 surrogate endpoint (Lee 2025, PMID 40739095)

Serial ECG and echo analyses in LIFE linked lower in-treatment electrical LVH and lower LV mass to fewer events after adjustment, but those analyses did not randomize the degree of regression (Okin 2004, PMID 15547161; Devereux 2004, PMID 15547162).

8. Remodeling is dynamic but not uniformly reversible

Regression depends on achieved pressure, duration, adherence, baseline geometry, obesity, renal disease and the tissue compartment measured. A fall in wall thickness can coexist with residual fibrosis; ECV fraction can change differently from absolute interstitial volume; and load-dependent strain can improve without structural reversal (González 2024, PMID 38084597; Lee 2025, PMID 40739095).

The REVERSE-LVH protocol deliberately separated ARNI from ARB and used CMR interstitial fibrosis volume as the primary endpoint; the completed trial supports differential remodeling at similar 52-week ambulatory SBP but not reduced HF or mortality (Lee 2023, PMID 37674806; Lee 2025, PMID 40739095; NCT03553810).

9. Experimental-to-clinical translation gaps

Claim Human evidence Missing proof
Fibrosis causes clinical transition Pathology, imaging association, mechanistic coherence Intervention-mediated event reduction
Microvascular dysfunction drives failure Flow and mechanistic studies HHD-specific targeted outcome trial
LVH regression improves prognosis Strong serial association Randomized regression-target strategy
ARNI has BP-independent antifibrotic action Small randomized imaging trials Large blinded clinical outcomes
Geometry guides therapy Prognostic cohorts Treatment-by-geometry interaction

Open questions

  • Does randomized targeting of a prespecified LV-mass, GLS or fibrosis change reduce clinical events beyond achieved BP? (Pierdomenico 2010, PMID 20414193; Lee 2025, PMID 40739095)
  • Which geometry transitions are causal rather than markers of ischemia, obesity, CKD or treatment exposure? (Nadruz 2015, PMID 24804791; Hwang 2025, PMID 40970541)
  • Can CMR interstitial volume, ECV and serum fibrosis markers be calibrated across platforms and linked to one actionable threshold? (González 2024, PMID 38084597; Lee 2025, PMID 40739095)
  • Does restoring coronary microvascular function prevent both HFpEF and arrhythmia in hypertensive LVH? (Camici 2020, PMID 31999329; Durante 2024, PMID 39769057)

References

  1. Nadruz W. Myocardial remodeling in hypertension. J Hum Hypertens. 2015;29:1-6. PMID 24804791
  2. Yildiz M, et al. Left ventricular hypertrophy and hypertension. Prog Cardiovasc Dis. 2020;63:10-21. PMID 31759953
  3. Stewart MH, et al. Prognostic Implications of Left Ventricular Hypertrophy. Prog Cardiovasc Dis. 2018;61:446-455. PMID 30408469
  4. Nwabuo CC, et al. Pathophysiology of Hypertensive Heart Disease: Beyond Left Ventricular Hypertrophy. Curr Hypertens Rep. 2020;22:11. PMID 32016791
  5. Nemtsova V, et al. Hypertensive Heart Disease: A Narrative Review Series-Part 1: Pathophysiology and Microstructural Changes. J Clin Med. 2023;12. PMID 37048689
  6. de Simone G, et al. Prognosis of inappropriate left ventricular mass in hypertension: the MAVI Study. Hypertension. 2002;40:470-6. PMID 12364349
  7. Woodiwiss AJ, et al. Obesity and left ventricular hypertrophy: the hypertension connection. Curr Hypertens Rep. 2015;17:539. PMID 25794954
  8. Weber KT. Fibrosis in hypertensive heart disease: focus on cardiac fibroblasts. J Hypertens. 2004;22:47-50. PMID 15106793
  9. González A, et al. Myocardial Interstitial Fibrosis in Hypertensive Heart Disease: From Mechanisms to Clinical Management. Hypertension. 2024;81:218-228. PMID 38084597
  10. Cuspidi C, et al. Hypertensive myocardial fibrosis. Nephrol Dial Transplant. 2006;21:20-3. PMID 16263734
  11. Sowers JR. Hypertension myocardial fibrosis. J Clin Hypertens (Greenwich). 2007;9:558-9. PMID 17617768
  12. Durante A, et al. Systemic and Cardiac Microvascular Dysfunction in Hypertension. Int J Mol Sci. 2024;25. PMID 39769057
  13. Camici PG, et al. Coronary microvascular dysfunction in hypertrophy and heart failure. Cardiovasc Res. 2020;116:806-816. PMID 31999329
  14. Paulus WJ, et al. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263-71. PMID 23684677
  15. Tadic M, et al. Effect of long-term antihypertensive therapy on myocardial strain: a meta-analysis. J Hypertens. 2022;40:641-647. PMID 35102087
  16. Hwang IC, et al. Left Ventricular Mass-to-Strain Ratio to Predict Change in Left Ventricular Hypertrophy and Prognosis in Hypertensive Heart Disease. J Am Heart Assoc. 2025;14:e042032. PMID 40970541
  17. Schmieder RE, et al. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA. 1996;275:1507-13. PMID 8622227
  18. Fagard RH, et al. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009;54:1084-91. PMID 19770405
  19. Devereux RB, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004;110:1456-62. PMID 15326072
  20. Pierdomenico SD, et al. Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis. Am J Hypertens. 2010;23:876-81. PMID 20414193
  21. Schmieder RE, et al. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur Heart J. 2017;38:3308-3317. PMID 29029087
  22. Lee V, et al. Effects of sacubitril/valsartan on hypertensive heart disease: the REVERSE-LVH randomized phase 2 trial. Nat Commun. 2025;16:6981. PMID 40739095
  23. Okin PM, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2343-9. PMID 15547161
  24. Devereux RB, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004;292:2350-6. PMID 15547162
  25. Lee V, et al. Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol. Front Cardiovasc Med. 2023;10:1248468. PMID 37674806